The Medicines Co. Newsletter
-
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
07 Jun 2024 14:46 GMT
… : ARCT), a global messenger RNA medicines company focused on the development of …
-
STAT+: ARCH, Medicines Co. veterans raise $290 million for in-licensed obesity drugs
18 Apr 2024 15:15 GMT
… veterans from Pfizer and The Medicines Company on its team, led the …
-
Mitsui and Rohto to buy US$594m Singapore-based Chinese medicines company Eu Yan Sang
05 Apr 2024 06:44 GMT
SINGAPORE, April 5 ― Japan's Mitsui & Co said yesterday it had teamed up with Rohto Pharmaceutical Co, to buy Eu Yan Sang International in a deal valuing the Singapore-based traditional Chinese medicines firm at S$800 million (RM2.8 billion).
…
-
Mitsui and Rohto to buy $594 million Chinese medicines company Eu Yan Sang
04 Apr 2024 10:12 GMT
SINGAPORE (Reuters) – Japan’s Mitsui & Co said on Thursday it had teamed up with Rohto Pharmaceutical Co to buy Eu Yan Sang International in a deal valuing the Singapore-based traditional Chinese medicines firm at S$800 million ($594 million).
Mitsui …
-
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
06 Jun 2024 11:30 GMT
… ), a leading clinical-stage genetic medicines company focused on unlocking the full … a leading clinical-stage genetic medicines company focused on unlocking the full …
-
Aptamer Group signs material agreement with genetic medicines company
20 Feb 2024 09:31 GMT
publication date: Feb 20, 2024
|
author/source: Aptamer Group
Optimer binders will be developed to support targeted genetic medicines to specific cell types
Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life …
-
Equities Analysts Issue Forecasts for Blueprint Medicines Co.’s FY2023 Earnings (NASDAQ:BPMC)
08 Feb 2024 13:31 GMT
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Analysts … worth $23,195,000.
Blueprint Medicines Company Profile
(Get Free Report)
Blueprint …
-
Leerink Partnrs Weighs in on Blueprint Medicines Co.’s Q1 2024 Earnings (NASDAQ:BPMC)
08 Feb 2024 08:15 GMT
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Analysts … during the last quarter.
Blueprint Medicines Company Profile
(Get Free Report)
Blueprint …
-
Daily Business Report: June 5, 2024
05 Jun 2024 12:35 GMT
… allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments …
-
Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 25,000 Shares
30 Jan 2024 13:28 GMT
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) … ratio of 4.09. Blueprint Medicines Co. has a fifty-two week … shares during the period.
Blueprint Medicines Company Profile
(Get Free Report)
Blueprint …